SiCare Bio

Executive Summary

SiCare Bio is a private preclinical biotechnology company headquartered in San Francisco, founded in 2020, with a workforce of 50-200 employees. The company is dedicated to developing innovative antibody-based therapeutics for oncology and autoimmune diseases. With a focus on leveraging antibody engineering to modulate immune responses, SiCare Bio aims to address high unmet medical needs in both cancer and autoimmune conditions. Despite being at a preclinical stage, the company has established a solid scientific foundation, as evidenced by its team and research focus. However, limited public information is available regarding specific pipeline candidates, financing history, or valuation, which is typical for a private early-stage biotech. The company's success will depend on advancing its lead programs into regulatory filing and securing funding or partnerships to support clinical development.

Upcoming Catalysts (preview)

• 2026Initiation of IND-Enabling Studies for Lead Antibody Candidate40% success
• H2 2026Presentation of Preclinical Data at Major Conference (e.g., ASCO or SITC)60% success
• 2027Strategic Partnership or Licensing Deal for Autoimmune Program30% success